Your browser doesn't support javascript.
loading
Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function.
Alba, M; Ahrén, B; Inzucchi, S E; Guan, Y; Mallick, M; Xu, L; O'Neill, E A; Williams-Herman, D E; Kaufman, K D; Goldstein, B J.
Afiliação
  • Alba M; Merck & Co., Inc., Whitehouse Station, NJ, USA.
Diabetes Obes Metab ; 15(12): 1101-10, 2013 Dec.
Article em En | MEDLINE | ID: mdl-23782502
ABSTRACT

AIMS:

The effects of sitagliptin and pioglitazone, alone and in combination, on α- and ß-cell function were assessed in patients with type 2 diabetes.

METHODS:

Following a 6-week diet/exercise period, 211 patients with HbA1c of 6.5-9.0% and fasting plasma glucose of 7.2-14.4 mmol/l were randomized (111 1) to sitagliptin, pioglitazone, sitagliptin + pioglitazone or placebo. At baseline and after 12 weeks, patients were given a mixed meal followed by frequent blood sampling for measurements of glucose, insulin, C-peptide and glucagon.

RESULTS:

After 12 weeks, 5-h glucose total area under the curve (AUC) decreased in all active treatments versus placebo; reduction with sitagliptin + pioglitazone was greater versus either monotherapy. The 5-h insulin total AUC increased with sitagliptin versus all other treatments and increased with sitagliptin + pioglitazone versus pioglitazone. The 3-h glucagon AUC decreased with sitagliptin versus placebo and decreased with sitagliptin + pioglitazone versus pioglitazone or placebo. Φ(s), a measure of dynamic ß-cell responsiveness to above-basal glucose concentrations, increased with either monotherapy versus placebo and increased with sitagliptin + pioglitazone versus either monotherapy. The insulin sensitivity index (ISI), a composite index of insulin sensitivity, improved with pioglitazone and sitagliptin + pioglitazone versus placebo. The disposition index, a measure of the relationship between ß-cell function and insulin sensitivity, improved with all active treatments versus placebo.

CONCLUSIONS:

Sitagliptin and pioglitazone enhanced ß-cell function (increasing postmeal Φ(s)), and sitagliptin improved α-cell function (decreasing postmeal glucagon) after 12 weeks in patients with type 2 diabetes. Through these complementary mechanisms of action, the combination of sitagliptin and pioglitazone reduced postmeal glucose more than either treatment alone.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirazinas / Triazóis / Tiazolidinedionas / Diabetes Mellitus Tipo 2 / Células Secretoras de Glucagon / Células Secretoras de Insulina / Hipoglicemiantes Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Aged / Humans / Middle aged Idioma: En Ano de publicação: 2013 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirazinas / Triazóis / Tiazolidinedionas / Diabetes Mellitus Tipo 2 / Células Secretoras de Glucagon / Células Secretoras de Insulina / Hipoglicemiantes Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Aged / Humans / Middle aged Idioma: En Ano de publicação: 2013 Tipo de documento: Article